Ménard S, Rilke F, Della Torre G, Mariani-Costantini R, Regazzoni M, Tagliabue E, Alasio L, Colnaghi M I
Am J Clin Pathol. 1985 May;83(5):571-6. doi: 10.1093/ajcp/83.5.571.
Cells from 229 pleural and peritoneal spontaneous fluids and 51 peritoneal lavage fluids from patients with neoplastic and nonneoplastic diseases were studied by indirect immunofluorescence with two monoclonal antibodies; MBr1, prepared against breast carcinoma, and MOv2, prepared against ovarian carcinoma. The results were correlated with those obtained by conventional cytologic methods. A cytologic diagnosis of metastatic carcinoma was established in about 50% of the fluids examined. Sixty percent of the cytologically malignant fluids contained tumor cells reactive with at least one of the two monoclonal antibodies tested. The specificity of the labeling was confirmed by immunoelectron microscopy. In addition, 16 fluids with a negative cytologic diagnosis contained cells strongly immunopositive with MBr1 and/or MOv2. Reactive mesothelial cells were consistently negative. These results suggest that antibodies MBr1 and MOv2 are able to identify cancer cells that do not fully meet conventional morphologic criteria for malignancy. The two reagents, when used in support of cytologic analysis, may substantially reduce the number of false negative cytologic diagnoses of fluids from patients with breast and ovarian carcinomas.
采用两种单克隆抗体，即针对乳腺癌制备的MBr1和针对卵巢癌制备的MOv2，通过间接免疫荧光法对来自229例患有肿瘤性和非肿瘤性疾病患者的胸腔和腹腔自发性积液以及51例腹腔灌洗液中的细胞进行了研究。将结果与通过传统细胞学方法获得的结果进行了相关性分析。在所检查的积液中，约50%的病例通过细胞学诊断为转移性癌。60%的细胞学诊断为恶性的积液中含有与所测试的两种单克隆抗体中的至少一种发生反应的肿瘤细胞。通过免疫电子显微镜证实了标记的特异性。此外，16例细胞学诊断为阴性的积液中含有与MBr1和/或MOv2呈强免疫阳性的细胞。反应性间皮细胞始终为阴性。这些结果表明，抗体MBr1和MOv2能够识别不完全符合传统恶性形态学标准的癌细胞。这两种试剂在辅助细胞学分析时，可能会大幅减少乳腺癌和卵巢癌患者积液的细胞学假阴性诊断数量。
